Communiqués GRI BIOPAR

Actions

GRI

US3622AW1069

Marché Fermé - Nasdaq 22:00:00 08/09/2026			Varia. 5j.	Varia. 1 janv.
2,000 ^USD	-30,56%		+50,00%	-70,15%

11/09/25	GRI Bio : Aucune Dégradation de la Fonction Pulmonaire Observée dans l'Étude de Phase 2a sur la Fibrose Pulmonaire Idiopathique	MT
01/04/25	GRI Bio propose une offre d'actions d'un montant maximal de 13 millions de dollars	MT

Communiqués

08/09	GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars	AQ
27/08	GRI Bio Featured in "Why Now" On-Demand Video Webcast	AQ
24/08	GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026	AQ
18/06	GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis	AQ
18/05	GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase	AQ
14/05	GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline	AQ
08/04	GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions	AQ
17/02	GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment	AQ
05/02	GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial	AQ
04/02	GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights	AQ
28/01	GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF	AQ
26/01	GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures	AQ
21/01	GRI Bio Announces Reverse Stock Split	AQ
08/01	GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621	AQ
12/12	GRI Bio Announces Closing of $8.0 Million Public Offering	AQ
11/12	GRI Bio Announces Pricing of $8,000,000 Million Public Offering	AQ
10/12	GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)	AQ
11/09/25	GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)	AQ
03/09/25	GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
15/08/25	GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series, Biotech, MedTech	AQ
14/08/25	GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech	AQ
31/07/25	GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment	AQ
31/07/25	GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)	AQ
22/07/25	GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference	AQ
01/07/25	GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	AQ